1. Home
  2. ARQT vs FSK Comparison

ARQT vs FSK Comparison

Compare ARQT & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$23.32

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

FSK

FS KKR Capital Corp.

HOLD

Current Price

$11.54

Market Cap

2.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARQT
FSK
Founded
2016
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
2.8B
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
ARQT
FSK
Price
$23.32
$11.54
Analyst Decision
Strong Buy
Hold
Analyst Count
6
8
Target Price
$34.00
$13.19
AVG Volume (30 Days)
905.0K
3.1M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
18.82%
EPS Growth
88.79
N/A
EPS
N/A
0.04
Revenue
$376,072,000.00
N/A
Revenue This Year
$34.85
N/A
Revenue Next Year
$29.39
N/A
P/E Ratio
N/A
$280.75
Revenue Growth
91.34
N/A
52 Week Low
$12.42
$9.72
52 Week High
$31.77
$22.68

Technical Indicators

Market Signals
Indicator
ARQT
FSK
Relative Strength Index (RSI) 48.06 61.20
Support Level $22.56 $9.85
Resistance Level $23.46 $15.19
Average True Range (ATR) 0.94 0.35
MACD -0.07 0.08
Stochastic Oscillator 36.38 96.09

Price Performance

Historical Comparison
ARQT
FSK

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

About FSK FS KKR Capital Corp.

FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.

Share on Social Networks: